摘要
目的分析阿帕替尼在晚期肺恶性肿瘤中的临床疗效。方法回顾性分析该科收治的60例晚期肺恶性肿瘤患者的临床资料,患者均选自2016年8月—2017年12月,全部采用最佳支持治疗,另予以30例观察组患者阿帕替尼,比较两组患者的近期疗效与肿瘤标志物水平。结果观察组血清癌胚抗原(CEA)、血管内皮生长因子(VEGF)、细胞角蛋白19片段(CYFRA21-1)与基质金属蛋白酶-9(MMP-9)治疗后分别为(14.03±1.15)ng·mL^(-4)、(4.19±0.58)ng·mL^(-4)、(291.85±51.49)ng·L^(-4)、(1 023.85±84.76 ab)ng·mL^(-4)、,对照组分别为(18.72±1.21) ng·mL^(-4)、(5.85±0.62)ng·mL^(-4)、(473.62±55.93)ng·L^(-4)、(1 405.21±110.53)ng·L^(-4),观察组各项指标均明显低于对照组,差异有统计学意义(t=-15.388,-10.709,-13.096,-15.388,-14.996,P<0.05;);观察组有效率为70.00%,对照组为36.66%,观察组近期疗效优于对照组,差异有统计学意义(χ~2=8.54,P<0.05)。结论阿帕替尼对于晚期肺恶性肿瘤患者有一定的治疗效果,临床用药期间应密切观察患者的不良反应,及时调整用药方案,谨慎用药。
Objective To analyze the clinical efficacy of apatinib in advanced lung malignancies. Methods The clinical data of 60 patients with advanced lung malignancies admitted to the department were retrospectively analyzed. All patients were selected from August 2016 to December 2017. All patients were treated with the best supportive therapy. Another 30 patients in the observation group were treated with Apa. For the two groups of patients, the short-term efficacy and tumor marker levels were compared. Results Serum carcinoembryonic antigen (CEA),cytokeratin 19 fragment (CYFRA21-1) vascular endothelial growth factor (VEGF), and matrix metalloproteinase-9 (MMP-9) were observed in the observation group (14.03±1.15)ng/mL^-4,(4.19±0.58) ng/mL^-4,(291.85±51.49) ng/L^-4,(1 023.85±84.76 ab) ng/mL^-4, and the control group were (18.72±1.21) ng/mL^-4,(5.85±0.62) ng/mL^-4,(473.62±55.93) ng/L^-4,(1 405.21±110.53) ng/L^-4, the indicators in the observation group were significantly lower than the control group,the different was statistically significant(t=-15.388,-10.709,-13.096,-15.388,-14.996, P<0.05); observation group of the effective rate was 70.00%, and the control group was 36.66%. The short-term effect of the observation group was better than that of the control group,the different was statistically significant(χ^2=8.54, P<0.05). Conclusion Apatinib has certain therapeutic effects on patients with advanced lung malignant tumors. During clinical use, patients should be closely observed for adverse reactions, timely adjusted the medication regimen, with careful use of drugs.
作者
齐倩
王春梅
杨娟
田英
冯超
QI Qian;WANG Chun-mei;YANG Juan;TIAN Ying;FENG Chao(Department of Oncology,People's Hospital of Cangzhou City,Cangzhou,Hebei Province,061000 China)
出处
《系统医学》
2018年第23期136-137,143,共3页
Systems Medicine
基金
阿帕替尼联合化疗治疗晚期非小细胞肺癌的临床研究(162302042)
关键词
阿帕替尼
晚期
恶性肿瘤
肺癌
治疗效果
Apatinib
Advanced
Malignant tumor
Lung cancer
Therapeutic effect
